Nanotheranostics in Cancer Treatment and Imaging

Nanotheranostics integrate diagnostic and therapeutic functions within a single nanoscale platform, enabling precise tumour localisation, real-time monitoring and targeted intervention. These systems often combine imaging modalities—such as magnetic resonance imaging, photoacoustic imaging, fluorescence or computed tomography—with therapeutic actions including photothermal therapy, photodynamic therapy, chemodynamic therapy and controlled drug release. By tuning physicochemical properties (surface chemistry, size, shape, composition), nanocarriers navigate the tumour microenvironment, accumulate via passive or active targeting and respond to internal stimuli (pH, enzymes, redox gradients) or external triggers (light, magnetic fields). Multifunctional nanoplatforms deliver cytotoxic agents or generate reactive oxygen species in situ, while providing enhanced contrast for early detection and image-guided therapy. Such advances reduce off-target effects and improve therapeutic indices, paving the way for personalised, minimally invasive cancer management with adaptive treatment paradigms.

Research from Nature Portfolio

Recent studies have demonstrated catalytic nanostructures that harness endogenous and exogenous resources for synergistic theranostics. Water-oxidation nanoframes derived from Prussian blue analogues self-supply O₂, H₂O₂ and hydroxyl radicals from water, driving chemodynamic therapy and near-infrared-mediated photothermal ablation. Proton-induced metal replacement creates separated active sites for water oxidation, oxygen reduction and Fenton-like catalysis, simultaneously generating imaging contrast and therapeutic oxidants. In a foundational example, systemic MEK inhibition has been combined with nanoparticle-mediated photothermal therapy to combat aggressive nerve-sheath tumours. Prussian blue nanoparticles convert light to heat, ablate cancer cells and synchronise with MEK blockade of Ras signalling, yielding pronounced tumour suppression. These works highlight the convergence of catalytic nanomaterials, molecularly targeted drugs and image-guided protocols to achieve precision nanochemotherapy.

Nanotheranostics in Cancer Treatment and Imaging publication trend

The graph below shows the total number of articles in nanotheranostics in cancer treatment and imaging across all publications each year (not limited to Nature Index journals).

Technical terms

Nanotheranostics: Integrated nanoscale systems combining diagnostic imaging and therapeutic functionalities in a single platform for cancer management.

Photothermal therapy (PTT): Treatment modality using light-absorbing agents to generate localised heat upon irradiation, inducing tumour cell death.

Photodynamic therapy (PDT): Therapy employing photosensitisers that produce cytotoxic reactive oxygen species upon light activation in the presence of oxygen.

Chemodynamic therapy (CDT): Approach utilising catalytic conversion of endogenous H₂O₂ into highly reactive hydroxyl radicals via Fenton or Fenton-like reactions within tumours.

Reactive oxygen species (ROS): Highly reactive molecules derived from oxygen (e.g. hydroxyl radicals, singlet oxygen) that mediate oxidative stress and cell damage.

Tumour microenvironment (TME): The local milieu of a tumour, including stromal cells, extracellular matrix, vasculature and biochemical gradients that influence therapeutic response.

Enhanced permeability and retention (EPR) effect: Passive targeting mechanism by which nanoscale materials accumulate preferentially in tumour tissue due to leaky vasculature and impaired lymphatic drainage.

References

1. Prussian blue analog with separated active sites to catalyze water driven enhanced catalytic treatments. Nature Communications (2023).
2. Injectable biocompatible nanocomposites of Prussian blue nanoparticles and bacterial cellulose as a safe and effective photothermal cancer therapy. Journal of Nanobiotechnology (2023).
3. Reactive oxygen species switcher via MnO2-coated Prussian blue loaded hyaluronic acid methacrylate hydrogel microspheres for local anti-tumor treatment. Journal of Controlled Release (2024).
4. Photothermal therapy improves the efficacy of a MEK inhibitor in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Scientific Reports (2016).
5. Mn doped Prussian blue nanoparticles for T1/T2 MR imaging, PA imaging and Fenton reaction enhanced mild temperature photothermal therapy of tumor. Journal of Nanobiotechnology (2022).